NCT06702488 Dexmedetomidine and Magnesium Sulfate in the Reduction Cognitive Dysfunction in Geriatrics
| NCT ID | NCT06702488 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Fayoum University |
| Condition | Mental Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 58 participants |
| Start Date | 2024-11-21 |
| Primary Completion | 2025-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 58 participants in total. It began in 2024-11-21 with a primary completion date of 2025-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Magnesium sulfate is considered a neuroprotective drug and has been studied in various applications. Recently, it has drawn the attention of anesthesiologists, resulting in numerous publications about its role in anesthesiology. Magnesium sulfate is suggested to exert its neuroprotective effect by preventing excitotoxicity. in the clinical setting, intraoperative magnesium sulfate attenuated POCD. Furthermore, postoperative emergence agitation was significantly reduced in pediatric patients who received intraoperative magnesium sulfate during adenotonsillectomy. The aim of this study The aim of this work is to compare the protective effect of intraoperative dexmedetomidine with magnesium sulfate against developing POCD and to study their effect on serum level of CRP; the marker of neuronal degeneration.
Eligibility Criteria
Inclusion Criteria: * ASA physical status I, II and ⅠⅠⅠ * patients undergoing open abdominal surgery under general anesthesia Exclusion Criteria: * Elderly patients with preoperative MoCA Score below 26. * Operation time more than 4 hours to prevent excessive dosage of magnesium sulfate. * BMI \> 35 kg m-2
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06702488 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 80 Years, studying Mental Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06702488 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06702488 currently recruiting?
Yes, NCT06702488 is actively recruiting participants. Contact the research team at mah07@fayoum.edu.eg for enrollment information.
Where is the NCT06702488 trial being conducted?
This trial is being conducted at Al Fayyum, Egypt.
Who is sponsoring the NCT06702488 clinical trial?
NCT06702488 is sponsored by Fayoum University. The trial plans to enroll 58 participants.